• Consensus Rating: Buy
  • Consensus Price Target: $86.80
  • Forecasted Upside: 21.26 %
  • Number of Analysts: 15
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$71.58
▲ +1.69 (2.42%)

This chart shows the closing price for ALC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Alcon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ALC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ALC

Analyst Price Target is $86.80
▲ +21.26% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Alcon in the last 3 months. The average price target is $86.80, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 21.26% upside from the last price of $71.58.

This chart shows the closing price for ALC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 15 investment analysts is to buy stock in Alcon. This rating has held steady since August 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 8 hold ratings
  • 2 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 7 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/27/2022Deutsche Bank AktiengesellschaftLower Price TargetCHF 85 ➝ CHF 80N/A
5/12/2022JPMorgan Chase & Co.Lower Price TargetNeutral ➝ NeutralCHF 69 ➝ CHF 68.80N/A
5/12/2022StephensUpgradeEqual Weight ➝ Overweight$86.00 ➝ $92.00N/A
4/8/2022Needham & Company LLCInitiated CoverageBuy$95.00N/A
3/11/2022Bank of AmericaInitiated CoverageBuy$85.00N/A
2/18/2022JPMorgan Chase & Co.Lower Price TargetCHF 72.20 ➝ CHF 69N/A
2/17/2022Credit Suisse GroupBoost Price TargetOutperform$93.00 ➝ $96.00N/A
2/17/2022Morgan StanleyLower Price TargetEqual Weight$95.00 ➝ $92.00N/A
1/18/2022StephensDowngradeOverweight ➝ Equal Weight$90.00 ➝ $86.00N/A
1/7/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$95.00N/A
11/12/2021Credit Suisse GroupBoost Price TargetOutperform$90.00 ➝ $93.00N/A
11/11/2021JPMorgan Chase & Co.Reiterated RatingNeutralN/A
11/11/2021CitigroupBoost Price TargetNeutral$84.00 ➝ $87.00N/A
11/11/2021Morgan StanleyBoost Price TargetOverweight$92.00 ➝ $95.00N/A
9/30/2021OppenheimerInitiated CoverageMarket PerformN/A
9/13/2021Wells Fargo & CompanyBoost Price TargetOverweight$90.00 ➝ $93.00N/A
8/27/2021Berenberg BankReiterated RatingBuyN/A
8/23/2021UBS GroupUpgradeBuyN/A
8/23/2021CitigroupBoost Price TargetNeutral$72.00 ➝ $84.00N/A
8/20/2021Societe GeneraleReiterated RatingHoldN/A
8/19/2021JPMorgan Chase & Co.Reiterated RatingNeutralN/A
8/19/2021Credit Suisse GroupBoost Price TargetOutperform$86.00 ➝ $90.00N/A
8/19/2021Morgan StanleyBoost Price TargetOverweight$79.00 ➝ $92.00N/A
8/19/2021SVB LeerinkBoost Price TargetPositive ➝ Market Perform$71.00 ➝ $82.00N/A
8/19/2021Wells Fargo & CompanyBoost Price TargetPositive ➝ Overweight$83.00 ➝ $90.00N/A
8/19/2021StephensBoost Price TargetOverweight$79.00 ➝ $90.00N/A
8/19/2021BTIG ResearchBoost Price TargetBuy$80.00 ➝ $84.00N/A
7/14/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuy$74.00N/A
5/7/2021JPMorgan Chase & Co.Reiterated RatingNeutralN/A
5/6/2021CitigroupUpgradeSell ➝ NeutralN/A
4/1/2021Berenberg BankReiterated RatingBuyN/A
3/31/2021ArgusBoost Price Target$72.00 ➝ $78.00N/A
3/31/2021Jefferies Financial GroupBoost Price TargetBuy$82.00 ➝ $85.00N/A
3/29/2021Societe GeneraleReiterated RatingHoldN/A
3/29/2021BTIG ResearchUpgradeNeutral ➝ Buy$78.00N/A
3/25/2021Jefferies Financial GroupBoost Price TargetBuy$82.00 ➝ $85.00N/A
3/22/2021BTIG ResearchUpgradeNeutral ➝ Buy$78.00N/A
3/5/2021Berenberg BankReiterated RatingBuyN/A
3/3/2021Credit Suisse GroupBoost Price TargetOutperform$76.00 ➝ $86.00N/A
3/3/2021Morgan StanleyBoost Price TargetOverweight$75.00 ➝ $79.00N/A
2/26/2021Societe GeneraleUpgradeSell ➝ HoldN/A
2/25/2021Morgan StanleyReiterated RatingOverweight$75.00 ➝ $79.00N/A
2/25/2021Credit Suisse GroupBoost Price TargetOutperform$76.00 ➝ $86.00N/A
1/20/2021Berenberg BankReiterated RatingBuyN/A
12/15/2020Morgan StanleyBoost Price TargetOverweight$73.00 ➝ $75.00N/A
11/19/2020Berenberg BankReiterated RatingBuyN/A
11/16/2020JPMorgan Chase & Co.Reiterated RatingNeutralN/A
11/13/2020Credit Suisse GroupBoost Price TargetOutperform$71.00 ➝ $76.00N/A
11/12/2020Jefferies Financial GroupBoost Price TargetBuy$71.00 ➝ $78.00N/A
11/12/2020Morgan StanleyBoost Price TargetOverweight$66.00 ➝ $73.00N/A
11/12/2020SVB LeerinkBoost Price TargetMarket Perform$61.00 ➝ $67.00N/A
11/12/2020GuggenheimDowngradeBuy ➝ NeutralN/A
9/1/2020Berenberg BankReiterated RatingBuyN/A
8/27/2020Societe GeneraleDowngradeHold ➝ SellN/A
8/20/2020SVB LeerinkBoost Price TargetMarket Perform$57.00 ➝ $61.00N/A
8/17/2020Credit Suisse GroupReiterated RatingBuy$63.00N/A
7/6/2020KeyCorpInitiated CoverageSector WeightN/A
7/6/2020CitigroupDowngradeNeutral ➝ Sell$55.00N/A
6/16/2020GuggenheimUpgradeNeutral ➝ Buy$68.00N/A
5/21/2020JPMorgan Chase & Co.Reiterated RatingNeutralN/A
5/14/2020Wells Fargo & CompanyBoost Price TargetOverweight$58.00 ➝ $62.00N/A
5/14/2020SVB LeerinkBoost Price TargetMarket Perform$56.00 ➝ $57.00N/A
5/14/2020CitigroupBoost Price TargetNeutral$54.00 ➝ $55.00N/A
5/14/2020StephensUpgradeEqual Weight ➝ OverweightN/A
4/20/2020BTIG ResearchReiterated RatingHoldN/A
4/9/2020Wells Fargo & CompanyLower Price TargetOverweight$70.00 ➝ $58.00N/A
4/8/2020SVB LeerinkLower Price TargetMarket Perform$62.00 ➝ $56.00N/A
4/8/2020Robert W. BairdDowngradeOutperform ➝ Neutral$69.00 ➝ $58.00N/A
3/27/2020CitigroupLower Price TargetNeutral$63.00 ➝ $54.00N/A
3/27/2020Morgan StanleyLower Price TargetOverweight$70.00 ➝ $66.00N/A
3/27/2020Kepler Capital MarketsReiterated RatingSellN/A
3/26/2020ArgusUpgradeHold ➝ Buy$55.00N/A
3/24/2020Societe GeneraleUpgradeSell ➝ HoldN/A
3/23/2020StephensLower Price TargetEqual Weight$68.00 ➝ $50.00N/A
3/13/2020UBS GroupUpgradeNeutral ➝ BuyN/A
3/12/2020Berenberg BankReiterated RatingBuyN/A
3/11/2020SVB LeerinkLower Price TargetMarket Perform$68.00 ➝ $62.00N/A
3/10/2020Kepler Capital MarketsReiterated RatingSellN/A
3/6/2020Credit Suisse GroupReiterated RatingBuy$69.00N/A
3/4/2020CitigroupInitiated CoverageNeutral$63.00N/A
3/4/2020Redburn PartnersDowngradeNeutral ➝ SellN/A
2/27/2020Credit Suisse GroupBoost Price TargetOutperform$68.00 ➝ $72.00N/A
2/27/2020StephensBoost Price TargetEqual Weight$62.00 ➝ $68.00N/A
2/27/2020Kepler Capital MarketsReiterated RatingSellN/A
2/26/2020Berenberg BankUpgradeHold ➝ BuyN/A
1/8/2020ArgusInitiated CoverageHoldN/A
12/17/2019Morgan StanleyLower Price TargetOverweight$71.00 ➝ $70.00N/A
11/24/2019BTIG ResearchReiterated RatingHoldN/A
11/20/2019Berenberg BankReiterated RatingHoldN/A
11/11/2019Redburn PartnersUpgradeSell ➝ NeutralN/A
10/28/2019StephensInitiated CoverageEqual ➝ Equal WeightN/A
8/26/2019Credit Suisse GroupBoost Price TargetOutperform$68.00 ➝ $73.00N/A
8/21/2019BTIG ResearchReiterated RatingHoldN/A
8/21/2019Bank of AmericaReiterated RatingNeutral$62.00 ➝ $65.00N/A
8/16/2019Credit Suisse GroupSet Price TargetBuy$68.00N/A
7/16/2019Morgan StanleyBoost Price TargetOverweight$65.00 ➝ $71.00N/A
6/24/2019SVB LeerinkInitiated CoverageMarket Perform$62.00N/A
6/14/2019BTIG ResearchInitiated CoverageNeutral ➝ NeutralN/A
6/3/2019Credit Suisse GroupReiterated RatingOutperformN/A
5/10/2019Robert W. BairdInitiated CoverageOutperform$69.00 ➝ $68.00N/A
5/9/2019OppenheimerInitiated CoverageOutperform$69.00N/A
5/2/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$66.00N/A
4/18/2019BMO Capital MarketsInitiated CoverageMarket Perform ➝ Market PerformN/A
4/15/2019Jefferies Financial GroupInitiated CoverageBuyN/A
4/10/2019Societe GeneraleInitiated CoverageBuy ➝ BuyN/A
4/10/2019Berenberg BankInitiated CoverageHoldN/A
4/10/2019Morgan StanleyInitiated CoverageOverweight$65.00N/A
4/10/2019JPMorgan Chase & Co.Initiated CoverageNeutralN/A
4/10/2019UBS GroupInitiated CoverageNeutralN/A
4/9/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$66.00N/A
4/8/2019Cleveland ResearchInitiated CoverageNeutralN/A
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.56 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/6/2021
  • 8 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/5/2022
  • 1 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/4/2022
  • 1 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/6/2022
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/5/2022
  • 6 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
6/4/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/4/2022

Current Sentiment

  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Alcon logo
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for use in surgical procedures. Its cataract products include centurion vision system, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantables products, including AcrySof IQ IOLs products include monofocal IOLs and advanced technology IOLs under the PanOptix and ReSTOR brands for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers under the TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux brands. The company was formerly known as Alcon Universal S.A. and changed the name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.
Read More

Today's Range

Now: $71.58
Low: $69.50
High: $71.58

50 Day Range

MA: $70.84
Low: $64.25
High: $76.70

52 Week Range

Now: $71.58
Low: $63.92
High: $88.78

Volume

19,284 shs

Average Volume

879,251 shs

Market Capitalization

$35.08 billion

P/E Ratio

76.97

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Alcon?

The following equities research analysts have issued research reports on Alcon in the last year: Bank of America Co., Berenberg Bank, BTIG Research, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Societe Generale, Stephens, SVB Leerink LLC, TheStreet, UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for ALC.

What is the current price target for Alcon?

0 Wall Street analysts have set twelve-month price targets for Alcon in the last year. Their average twelve-month price target is $86.80, suggesting a possible upside of 21.3%.
View the latest price targets for ALC.

What is the current consensus analyst rating for Alcon?

Alcon currently has 6 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ALC will outperform the market and that investors should add to their positions of Alcon.
View the latest ratings for ALC.

How do I contact Alcon's investor relations team?

Alcon's physical mailing address is Rue Louis-d`Affry 6, Fribourg V8, 1701. The healthcare company's listed phone number is 41-58-911-2000 and its investor relations email address is [email protected] The official website for Alcon is www.alcon.com. Learn More about contacing Alcon investor relations.